Findings

What do systematic reviews say?

771 questions · 791 findings · 66 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 207 · 26.2%GRADE not reported 47 · 5.9%Very low 172 · 21.7%Low 211 · 26.7%Moderate 107 · 13.5%High 47 · 5.9%

Intervention not reported

Cervical cancer ‐ not measured · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Cervical cancer ‐ not measured · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

CIN2+ associated with HPV16/18 · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination

The intervention leads to lower CIN2+ associated with HPV16/18 (high certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.05 [0.03, 0.1]
6 studies · 34478 participants
High

Intervention not reported

CIN3+ associated with HPV16/18 (age 15 to 26 years) · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination

The intervention leads to lower CIN3+ associated with HPV16/18 (age 15 to 26 years) (high certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.05 [0.02, 0.14]
3 studies · 33199 participants
High

Intervention not reported

AIS associated with HPV16/18 or 6/11/16/18 (age 15 to 26 years) · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination

The intervention probably leads to lower AIS associated with HPV16/18 or 6/11/16/18 (age 15 to 26 years) (moderate certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.09 [0.01, 0.72]
2 studies · 17079 participants
Moderate

Intervention not reported

Any CIN2+ irrespective of HPV type (age 15 to 26 years) · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination

The intervention leads to lower any CIN2+ irrespective of HPV type (age 15 to 26 years) (high certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.41 [0.32, 0.52]
3 studies · 19143 participants
High

Intervention not reported

Any CIN3+ irrespective of HPV type ‐ not measured · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Any AIS irrespective of HPV type ‐ not measured · adolescent girls and women aged 15 to 45 years who were HPV16/18 negative before vaccination

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Cervical cancer ‐ not measured · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline

The review found no eligible studies for this question.

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

CIN2+ associated with HPV16/18 · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline

The intervention leads to lower CIN2+ associated with HPV16/18 (high certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.46
3 studies · 34852 participants
High

Intervention not reported

CIN3+ associated with HPV16/18 · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline

The intervention leads to lower CIN3+ associated with HPV16/18 (high certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.55 [0.45, 0.67]
2 studies · 34562 participants
High

Intervention not reported

CIN2+ associated with HPV16/18. · adolescent girls and women aged 15 to 26 years who are hrHPV negative before vaccination

The intervention leads to lower CIN2+ associated with HPV16/18. (high certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.01 [0, 0.05]
3 studies · 23676 participants
High

Intervention not reported

Adeno carcinoma in situ (AIS) associated with HPV16/18 · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline

The intervention leads to lower adeno carcinoma in situ (AIS) associated with HPV16/18 (high certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.36 [0.17, 0.78]
2 studies · 34562 participants
High

Intervention not reported

Any CIN2+ irrespective of HPV type · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline

The intervention leads to lower any CIN2+ irrespective of HPV type (high certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.7 [0.58, 0.85]
4 studies · 35779 participants
High

Intervention not reported

Any CIN3+ irrespective of HPV type (age 15 to 26 years) · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline

The intervention probably leads to lower any CIN3+ irrespective of HPV type (age 15 to 26 years) (moderate certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.67 [0.49, 0.93]
3 studies · 35489 participants
Moderate

Intervention not reported

Any CIN3+ irrespective of HPV type (age 15 to 26 years), · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline

The intervention leads to lower any CIN3+ irrespective of HPV type (age 15 to 26 years), (high certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.55 [0.43, 0.71]
2 studies · 18329 participants
High

Intervention not reported

Any AIS irrespective of HPV type (age 15 to 26 years) · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline

The intervention leads to lower any AIS irrespective of HPV type (age 15 to 26 years) (high certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.32 [0.15, 0.67]
2 studies · 34562 participants
High

Intervention not reported

Serious adverse events · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline

The intervention showed no clear difference in serious adverse events (high certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.98 [0.92, 1.05]
23 studies · 71597 participants
High

Intervention not reported

Deaths · adolescent girls and women aged 15 to 45 years regardless of HPV DNA status at baseline

The intervention showed no clear difference in deaths (low certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 1.29 [0.85, 1.98]
23 studies · 71176 participants
Low

Intervention not reported

Spontaneous abortion/miscarriage · adolescent girls and women aged 15 to 45 years who became pregnant during the study

The intervention showed no clear difference in spontaneous abortion/miscarriage (high certainty).

1 finding from 1 review

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors 2018 · Cochrane Headline outcomes only
RR 0.88 [0.68, 1.14]
9 studies · 8618 participants
High